MDL Track
MDL 3094
E.D. Pa.
GLP-1 receptor agonist (Ozempic) gastroparesis track
3,363 pending
Pharmaceutical · litigation and safety scrutiny around semaglutide products and severe gastrointestinal injuries including gastroparesis
Defendant
Novo Nordisk A/S
MDL / Track
MDL 3094
E.D. Pa.
Judge
Judge Karen Spencer Marston
Plaintiffs
3,063 pending
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Gastroparesis claims against Novo Nordisk continue to accumulate in the Ozempic GLP-1 MDL following the January 2025 label update that added a contraindication stating Ozempic is "not recommended in patients with severe gastroparesis"—but plaintiffs allege the label still fails to warn that the drug itself may cause the condition. As of February 2026, approximately 3,191 lawsuits are pending across consolidated proceedings, with core allegations centering on failure to warn, inadequate safety information provided to prescribers, and severe gastrointestinal injuries including delayed gastric emptying requiring hospitalization and feeding tube placement.
Causation Theory
Semaglutide, a GLP-1 receptor agonist, slows gastric motility by inhibiting postprandial antral contractions and accelerating pyloric pressure waves, creating a functional obstruction that can progress to clinically significant gastroparesis. A 2025 Cureus case report documented semaglutide-induced gastroparesis following rapid dose escalation to 2 mg without titration, resulting in acute kidney injury secondary to dehydration; the report cites data showing 19% of GLP-1 agonist patients develop delayed gastric emptying, with semaglutide carrying a 3.3-fold higher gastroparesis risk than bupropion-naltrexone. The FDA has confirmed receipt of adverse event reports linking semaglutide and liraglutide to gastroparesis, including cases documented as "not recovered after discontinuation."
Case Management Orders
Litigation status
MDL 3094 gastroparesis claims proceed in the Eastern District of Pennsylvania under Judge Karen Spencer Marston following her August 15, 2025 ruling that narrowed but preserved the litigation by requiring gastric emptying study documentation. Daubert motions were due October 27, 2025; bellwether trials are anticipated for late 2026.
MDL Track
MDL 3094
E.D. Pa.
GLP-1 receptor agonist (Ozempic) gastroparesis track
3,363 pending
State Court Activity
30+ NAION plaintiffs seeking New Jersey state court consolidation — excluded from MDL 3094 per January 2025 JPML decision
MDL 3094 Leadership
Plaintiff Leadership
Co-Lead Counsel
Liaison Counsel
Geographic exposure
FDA label updated January 2025 to state Ozempic is 'not recommended in patients with severe gastroparesis'; October 2025 label revision added 'intestinal obstruction, severe constipation including fecal impaction' to postmarketing experience
MDL No. 3094 (In Re: GLP-1 Receptor Agonists Products Liability Litigation) before Judge Karen Spencer Marston; 3,191 total lawsuits as of February 2026; discovery phase active, bellwether selection expected 2026
First individual gastroparesis lawsuit filed (2:23-cv-01020-JDC-KK); early bellwether candidate jurisdiction
Hill v. Novo Nordisk filed August 2024 alleging bowel obstruction and stomach paralysis
Active filings in October-December 2023 surge; San Diego-based firms reporting hospitalized claimant intake
Surge jurisdiction in initial 2023 filing wave; Morgan & Morgan actively reviewing hospitalized gastroparesis diagnoses
Surge jurisdiction in initial 2023 filing wave
Novo Nordisk home state; New Jersey Supreme Court permitting state-level consolidation of GLP-1 injury cases parallel to federal MDL
Key defendants
Novo Nordisk A/S
Role: Manufacturer
Aggressive dismissal posture in MDL 3094; filed Feb. 2025 motion before Judge Marston seeking to eliminate breach of warranty, design defect, negligence and medical monitoring claims. Lost individual dismissal bid in W.D. La. (Judge Cain, Dec. 2024) on failure-to-warn but preserved express warranty win. Core exposure remains gastroparesis/ileus warnings.
Eli Lilly and Company
Role: Manufacturer
Co-defendant with Novo Nordisk in MDL 3094; joined dismissal motion targeting 'extraneous' claims beyond failure-to-warn. Individual dismissal bid in Bjorklund (W.D. La.) rejected. Exposure tied to Trulicity and Mounjaro GI injury claims; indemnity posture unclear.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Novo Nordisk A/S | Manufacturer | Aggressive dismissal posture in MDL 3094; filed Feb. 2025 motion before Judge Marston seeking to eliminate breach of warranty, design defect, negligence and medical monitoring claims. Lost individual dismissal bid in W.D. La. (Judge Cain, Dec. 2024) on failure-to-warn but preserved express warranty win. Core exposure remains gastroparesis/ileus warnings. |
| Eli Lilly and Company | Manufacturer | Co-defendant with Novo Nordisk in MDL 3094; joined dismissal motion targeting 'extraneous' claims beyond failure-to-warn. Individual dismissal bid in Bjorklund (W.D. La.) rejected. Exposure tied to Trulicity and Mounjaro GI injury claims; indemnity posture unclear. |
Timeline
First Gastroparesis Lawsuit Filed
Jaclyn Bjorklund files first Ozempic gastroparesis lawsuit in Louisiana against Novo Nordisk and Eli Lilly, alleging stomach paralysis after taking Ozempic and Mounjaro.
FDA Adds Ileus Warning to Ozempic Label
FDA requires addition of ileus to Ozempic prescribing information, marking first regulatory acknowledgment of serious GI injury risk.
MDL 3094 Formed in E.D. Pa.
JPML consolidates 55 cases into MDL 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, assigned to Eastern District of Pennsylvania.
Judge Pratter Dies; MDL Reassigned
U.S. District Judge Gene E.K. Pratter, presiding over MDL 3094, dies unexpectedly May 17.
Judge Marston Takes MDL 3094
U.S. District Judge Karen Spencer Marston appointed to preside over MDL 3094 following three-week gap.
Master Complaint Filed
Plaintiffs file consolidated master complaint alleging failure to warn. Complaint cites FDA FAERS data showing nearly 500 U.S. deaths linked to semaglutide medications.
JPML Expands MDL to Include Saxenda
JPML expands MDL 3094 scope to include Novo Nordisk's Saxenda. Declines to add blood clot injury cases, maintaining focus on GI injuries.
MDL 3094 Reaches 1,521 Pending Cases
MDL 3094 docket grows to 1,521 pending lawsuits as of March 3. Internal poll indicates approximately 7,000 additional cases under investigation. Court schedules evidentiary hearing for May 20, 2025.
New Jersey MCL Approved for Gastroparesis
New Jersey Supreme Court approves multicounty litigation for Ozempic gastroparesis lawsuits, creating state-coordinated venue parallel to federal MDL.
Statute of limitations
MDL 3094 (gastroparesis/GI injury) split from NAION track (MDL 3163) December 2025 per JPML order. Both assigned to Judge Karen Spencer Marston, E.D. Pa. No federal preemption ruling yet; preemption defenses expected in April 2026 summary judgment briefing. Tolling agreements not publicly disclosed. Screen for: (1) brand-name use only; (2) gastroparesis diagnosis with hospitalization/ER visit; (3) temporal proximity to GLP-1 use. Source: Shouse Law (Jan. 2026), Seeger Weiss (Apr. 2025).
⚠Kentucky
1 year from injury
Rule: Ky. Rev. Stat. § 413.140(1)(a); strict 1-year personal injury SOL
Discovery: Discovery rule may apply but courts construe narrowly; defendant will argue earliest possible accrual
Shortest SOL in major plaintiff states. Immediate intake screening required. Source: Noakes Law Group analysis (2025).
⚠Louisiana
1 year from injury
Rule: La. Civ. Code art. 3492; early filings in W.D. La. (2:23-cv-01020-JDC-KK)
Discovery: Discovery rule recognized but applied restrictively; contra non valentem doctrine available for fraudulent concealment
Pioneer filings state. 1-year window creates intake pressure. Individual filings only, not class action. Source: Lawsuit Legal (2024).
Indiana
2 years from injury
Rule: Ind. Code § 34-11-2-4; product liability claims accrue when injury occurs
Discovery: Discovery rule recognized but limited; statutory text focuses on 'occurrence' of injury
No pending revival legislation. Source: Noakes Law Group analysis (2025).
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule standard for product liability
Discovery: Injury must be discovered or discoverable by reasonable diligence; delayed diagnosis claims viable
Largest plaintiff pool. Source: TruLaw analysis (2024).
Pennsylvania
2 years from discovery
Rule: 42 Pa. Cons. Stat. § 5524(2); MDL 3094 situs
Discovery: Discovery rule applies; accrual when plaintiff knows or should know of injury and its cause
MDL 3094 (In re: Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation) centralized before Judge Karen Spencer Marston, E.D. Pa. Summary judgment motions scheduled April 2026. Bellwether trials expected late 2026-2027. Source: Shouse Law (Jan. 2026).
Maine
6 years from discovery
Rule: 14 Me. Rev. Stat. § 859; longest SOL for product liability
Discovery: Discovery rule applies; 6-year window from when injury discovered or should have been discovered
Favorable for delayed diagnosis cases. Source: TruLaw analysis (2024).
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| ⚠Kentucky | 1 year from injury | Ky. Rev. Stat. § 413.140(1)(a); strict 1-year personal injury SOL | Discovery rule may apply but courts construe narrowly; defendant will argue earliest possible accrual | Shortest SOL in major plaintiff states. Immediate intake screening required. Source: Noakes Law Group analysis (2025). |
| ⚠Louisiana | 1 year from injury | La. Civ. Code art. 3492; early filings in W.D. La. (2:23-cv-01020-JDC-KK) | Discovery rule recognized but applied restrictively; contra non valentem doctrine available for fraudulent concealment | Pioneer filings state. 1-year window creates intake pressure. Individual filings only, not class action. Source: Lawsuit Legal (2024). |
| Indiana | 2 years from injury | Ind. Code § 34-11-2-4; product liability claims accrue when injury occurs | Discovery rule recognized but limited; statutory text focuses on 'occurrence' of injury | No pending revival legislation. Source: Noakes Law Group analysis (2025). |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 335.1; discovery rule standard for product liability | Injury must be discovered or discoverable by reasonable diligence; delayed diagnosis claims viable | Largest plaintiff pool. Source: TruLaw analysis (2024). |
| Pennsylvania | 2 years from discovery | 42 Pa. Cons. Stat. § 5524(2); MDL 3094 situs | Discovery rule applies; accrual when plaintiff knows or should know of injury and its cause | MDL 3094 (In re: Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation) centralized before Judge Karen Spencer Marston, E.D. Pa. Summary judgment motions scheduled April 2026. Bellwether trials expected late 2026-2027. Source: Shouse Law (Jan. 2026). |
| Maine | 6 years from discovery | 14 Me. Rev. Stat. § 859; longest SOL for product liability | Discovery rule applies; 6-year window from when injury discovered or should have been discovered | Favorable for delayed diagnosis cases. Source: TruLaw analysis (2024). |
Live intelligence
AI litigation brief
Ozempic Gastroparesis remains mid-stage / active mdl with 149 current signals in the accepted feed.
Overview
MDL 3094 gastroparesis claims proceed in the Eastern District of Pennsylvania under Judge Karen Spencer Marston following her August 15, 2025 ruling that narrowed but preserved the litigation by requiring gastric emptying study documentation. Daubert motions were due October 27, 2025; bellwether trials are anticipated for late 2026.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3094, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3094 should stay on the lead docket watch because it is the primary consolidation vehicle for Ozempic Gastroparesis.
Generated Apr 28, 2026, 1:00 AM UTC
149 events detected
Google News (6)
Stomach paralysis death triggers lawsuit against Ozempic maker - NewsNation
Stomach paralysis death triggers lawsuit against Ozempic maker - Yahoo
Ozempic Maker Sued After Woman Died From Stomach Paralysis - Newsweek
Ozempic Maker Sued After Woman Died From Stomach Paralysis - Newsweek
Ozempic Gastroparesis Lawsuits Grow as Patients Report Severe Stomach Problems - JD Supra
Ozempic Gastroparesis Lawsuits Grow as Patients Report Severe Stomach Problems - jdsupra.com
Journal of neurogastroenterology and motility • Ho V • PMID 41952406 • Journal Article.
Journal of the American Pharmacists Association : JAPhA • Rosario N • PMID 41794178 • Journal Article.
Acta gastro-enterologica Belgica • Delire B • PMID 41745643 • Case Reports.
Cureus • Kashyap R • PMID 41913883 • Case Reports.
Anaesthesia • Saldien V • PMID 41631344 • Journal Article.
RAGSDALE v. NOVO NORDISK, INC.
Eastern District of Pennsylvania
Federal court result for Ozempic Gastroparesis: COMPLAINT SHORT FORM COMPLAINT AND DEMAND FOR A JURY TRIAL against All Defendants ( Filing fee $ 405 receipt number APAEDC-19206236.), filed by BETTY JO RAGSDALE. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(RUANE, SARAH) (Entered: 04/27/2026) • Complaint (Attorney) • District Court, E.D. Pennsylvania • 2:26-cv-02773
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT against ELI LILLY AND COMPANY, LILLY USA, LLC ( Filing fee $ 405 receipt number APAEDC-19202602.), filed by CAROLYN NUCKOLS. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 04/24/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT against ELI LILLY AND COMPANY, LILLY USA, LLC ( Filing fee $ 405 receipt number APAEDC-19202504.), filed by GREGORY NEWSOME. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 04/24/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT against NOVO NORDISK A/S, NOVO NORDISK INC., ( Filing fee $ 405 receipt number APAEDC-19202442.), filed by LELIA ECHOLS. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 04/24/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT ON BEHALF OF THE ESTATE OF BILLY DON BISHOP, against NOVO NORDISK A/S, NOVO NORDISK INC ( Filing fee $ 405 receipt number APAEDC-19202396.), filed by ELANIA BISHOP. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(AMINOLROAYA, PARVIN) (Entered: 04/24/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT Karen M. Upshur against All Defendants ( Filing fee $ 405 receipt number APAEDC-19201906.), filed by Karen M. Upshur. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Kelley, Edward) (Entered: 04/24/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from NYED: COMPLAINT against Novo Nordisk A/S, Novo Nordisk Inc. filing fee $ 405, receipt number ANYEDC-20148405 Was the Disclosure Statement on Civil Cover Sheet completed -YES,, filed by Teamsters Local 237 Retiree Fund. (Attachments: # 1 Civil Cover Sheet, # 2 Proposed Summons Novo Nordisk Inc., # 3 Propo
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: NOTICE OF REMOVAL by ELI LILLY AND COMPANY, LILLY USA, LLC from New Jersey Superior Court, Law Div, Bergen County, case number BER-L-003909-26. ( Filing and Admin fee $ 405 receipt number ANJDC-17298651), filed by ELI LILLY AND COMPANY, LILLY USA, LLC. (Attachments: # 1 Exhibit A, # 2 Certificate o
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT Penny L. Tipton against All Defendants ( Filing fee $ 405 receipt number APAEDC-19198394.), filed by Penny L. Tipton. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Kelley, Edward) (Entered: 04/23/2026)
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability (Gastroparesis) Litigation
PACER docket entry from PAED: COMPLAINT Craig Yates against All Defendants ( Filing fee $ 405 receipt number APAEDC-19198381.), filed by Craig Yates. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(Kelley, Edward) (Entered: 04/23/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Apr 28, 2026, 1:00 AM UTC
Next: 35:42
Source Monitoring
PACER
PACER
Google News
FDA
PubMed
Event feed
149
events detected
AI Brief
Ozempic Gastroparesis remains mid-stage / active mdl with 149 current signals in the accepted feed.
Overview
MDL 3094 gastroparesis claims proceed in the Eastern District of Pennsylvania under Judge Karen Spencer Marston following her August 15, 2025 ruling that narrowed but preserved the litigation by requiring gastric emptying study documentation. Daubert motions were due October 27, 2025; bellwether trials are anticipated for late 2026.
Key developments
PACER court filing on Apr 27: RAGSDALE v. NOVO NORDISK, INC.. ‖ NewsNation news on Mar 17: Stomach paralysis death triggers lawsuit against Ozempic maker - NewsNation. ‖ openFDA recall on Feb 26: FDA Recall: Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only. ‖ PubMed research on Apr 30: Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study..
Generated Apr 28, 2026, 1:00 AM UTC
Tracked MDLs
MDL 3094
E.D. Pa.
GLP-1 receptor agonist (Ozempic) gastroparesis track